Why BofA worries about Hims & Hers. Hims & Hers stock has been a mega-outperformer for investors, growing more than 600% over ...
Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...
New service will enable blood testing for hormone levels, cardiac risk, thyroid function, and more using a blood lancet.
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...
Shares of Hims & Hers (NYSE: HIMS) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the ...
Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...
Bullish option flow detected in Hims and Hers Health with 70,176 calls trading, 5x expected, and implied vol increasing almost 17 points to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results